Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B-Lymphocyte Subsets | 14 | 2020 | 18 | 4.700 |
Why?
|
| B-Lymphocytes | 24 | 2019 | 74 | 4.070 |
Why?
|
| Immunoglobulin M | 10 | 2020 | 17 | 2.560 |
Why?
|
| T-Lymphocytes | 5 | 2020 | 124 | 2.310 |
Why?
|
| Mice, Inbred C57BL | 22 | 2020 | 767 | 2.130 |
Why?
|
| Antibody Formation | 9 | 2019 | 46 | 2.010 |
Why?
|
| Mice | 42 | 2020 | 2484 | 1.870 |
Why?
|
| Peritoneal Neoplasms | 3 | 2020 | 259 | 1.610 |
Why?
|
| Cord Factors | 3 | 2020 | 3 | 1.600 |
Why?
|
| Lipid A | 3 | 2020 | 4 | 1.600 |
Why?
|
| Lymphocyte Activation | 11 | 2020 | 88 | 1.510 |
Why?
|
| Streptococcus pneumoniae | 5 | 2019 | 40 | 1.350 |
Why?
|
| Animals | 48 | 2020 | 7541 | 1.350 |
Why?
|
| Receptors, Complement 3d | 9 | 2009 | 12 | 1.320 |
Why?
|
| Adjuvants, Immunologic | 8 | 2020 | 55 | 1.300 |
Why?
|
| Antigens, CD19 | 8 | 2018 | 9 | 1.290 |
Why?
|
| Immunity, Innate | 5 | 2018 | 75 | 1.290 |
Why?
|
| Immunoglobulin G | 11 | 2020 | 122 | 1.290 |
Why?
|
| Antigens, T-Independent | 3 | 2020 | 3 | 1.200 |
Why?
|
| Mice, Knockout | 16 | 2020 | 443 | 1.150 |
Why?
|
| Receptors, Complement 3b | 5 | 2009 | 8 | 1.120 |
Why?
|
| Pneumococcal Infections | 4 | 2019 | 31 | 1.110 |
Why?
|
| Pneumococcal Vaccines | 3 | 2019 | 26 | 1.090 |
Why?
|
| Antibodies, Bacterial | 5 | 2019 | 32 | 1.080 |
Why?
|
| Lectins, C-Type | 3 | 2020 | 13 | 1.040 |
Why?
|
| Toll-Like Receptors | 3 | 2020 | 23 | 1.030 |
Why?
|
| Signal Transduction | 14 | 2020 | 682 | 0.990 |
Why?
|
| Immunologic Memory | 3 | 2020 | 32 | 0.900 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2020 | 11 | 0.890 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2020 | 40 | 0.830 |
Why?
|
| Cell Differentiation | 7 | 2020 | 469 | 0.820 |
Why?
|
| Peritoneal Cavity | 3 | 2018 | 6 | 0.730 |
Why?
|
| Antigens, Ly | 1 | 2020 | 6 | 0.720 |
Why?
|
| Interferon Type I | 1 | 2020 | 11 | 0.710 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 2 | 2016 | 3 | 0.710 |
Why?
|
| Polysaccharides, Bacterial | 5 | 2015 | 10 | 0.710 |
Why?
|
| Polysaccharides | 1 | 2019 | 13 | 0.660 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 14 | 0.640 |
Why?
|
| Cells, Cultured | 13 | 2019 | 833 | 0.640 |
Why?
|
| Receptors, Antigen, B-Cell | 8 | 2018 | 11 | 0.610 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 5 | 0.600 |
Why?
|
| Autoantibodies | 3 | 2014 | 49 | 0.590 |
Why?
|
| Gene Expression Regulation | 5 | 2015 | 495 | 0.510 |
Why?
|
| Complement C4 | 1 | 2014 | 4 | 0.490 |
Why?
|
| Primates | 1 | 2015 | 108 | 0.490 |
Why?
|
| Streptococcal Infections | 1 | 2014 | 22 | 0.490 |
Why?
|
| Antigens | 2 | 2013 | 31 | 0.450 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2013 | 12 | 0.450 |
Why?
|
| Epitopes | 1 | 2013 | 24 | 0.440 |
Why?
|
| Cell Proliferation | 5 | 2020 | 604 | 0.440 |
Why?
|
| Antigens, CD20 | 6 | 2010 | 7 | 0.430 |
Why?
|
| Down-Regulation | 2 | 2019 | 142 | 0.420 |
Why?
|
| Growth Inhibitors | 2 | 2011 | 10 | 0.410 |
Why?
|
| Macrophages | 4 | 2020 | 191 | 0.400 |
Why?
|
| Neoplasms | 3 | 2016 | 726 | 0.390 |
Why?
|
| Antigens, Surface | 2 | 2015 | 24 | 0.370 |
Why?
|
| Immunity, Humoral | 5 | 2015 | 13 | 0.350 |
Why?
|
| Cattle | 6 | 2003 | 103 | 0.350 |
Why?
|
| Lupus Nephritis | 1 | 2010 | 30 | 0.350 |
Why?
|
| Immunization | 4 | 2016 | 33 | 0.340 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2020 | 16 | 0.340 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 40 | 0.340 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 148 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 6 | 2010 | 246 | 0.320 |
Why?
|
| Complement C3d | 2 | 2005 | 2 | 0.310 |
Why?
|
| Autoimmunity | 2 | 2005 | 32 | 0.310 |
Why?
|
| Lymphocyte Depletion | 6 | 2010 | 17 | 0.300 |
Why?
|
| Leukemia, B-Cell | 1 | 2006 | 5 | 0.280 |
Why?
|
| Female | 10 | 2020 | 19959 | 0.280 |
Why?
|
| Male | 8 | 2019 | 19165 | 0.240 |
Why?
|
| Phagocytes | 2 | 2020 | 5 | 0.240 |
Why?
|
| Mice, Transgenic | 4 | 2016 | 264 | 0.240 |
Why?
|
| Homeostasis | 2 | 2017 | 132 | 0.230 |
Why?
|
| Immunotherapy | 5 | 2008 | 81 | 0.230 |
Why?
|
| Bacterial Vaccines | 2 | 2019 | 8 | 0.220 |
Why?
|
| Cell Division | 3 | 2020 | 99 | 0.220 |
Why?
|
| Antibodies | 2 | 2008 | 52 | 0.220 |
Why?
|
| Trinitrobenzenes | 2 | 2013 | 2 | 0.210 |
Why?
|
| Ficoll | 2 | 2013 | 3 | 0.210 |
Why?
|
| Macaca fascicularis | 2 | 2015 | 434 | 0.210 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1022 | 0.200 |
Why?
|
| Lymphoma, B-Cell | 3 | 2012 | 11 | 0.200 |
Why?
|
| Trypanosoma congolense | 1 | 2001 | 1 | 0.200 |
Why?
|
| Trypanosomiasis, African | 1 | 2001 | 6 | 0.200 |
Why?
|
| Ligands | 5 | 2007 | 81 | 0.190 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2020 | 5 | 0.190 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2020 | 2 | 0.180 |
Why?
|
| Immunoglobulin A | 2 | 2014 | 12 | 0.180 |
Why?
|
| Carrier Proteins | 1 | 2001 | 136 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 170 | 0.170 |
Why?
|
| Lymphoma | 1 | 2020 | 35 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 115 | 0.170 |
Why?
|
| Antigens, Nuclear | 1 | 2019 | 7 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2001 | 256 | 0.170 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2019 | 5 | 0.170 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 17 | 0.170 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 288 | 0.170 |
Why?
|
| Antibody-Producing Cells | 1 | 2019 | 3 | 0.170 |
Why?
|
| Apoptosis | 2 | 2020 | 360 | 0.160 |
Why?
|
| Disease Susceptibility | 2 | 2013 | 57 | 0.160 |
Why?
|
| Vaccines, Conjugate | 1 | 2019 | 17 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2012 | 28 | 0.160 |
Why?
|
| Mice, Inbred A | 1 | 2018 | 4 | 0.160 |
Why?
|
| DNA Repair | 1 | 2019 | 64 | 0.160 |
Why?
|
| Protein Binding | 4 | 2019 | 201 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 261 | 0.160 |
Why?
|
| Humans | 13 | 2020 | 32005 | 0.160 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 3 | 0.150 |
Why?
|
| Interleukin-5 | 1 | 2017 | 5 | 0.150 |
Why?
|
| Syndecan-1 | 1 | 2017 | 11 | 0.150 |
Why?
|
| Complement System Proteins | 2 | 2009 | 9 | 0.150 |
Why?
|
| Vaccination | 1 | 2019 | 138 | 0.150 |
Why?
|
| Receptors, IgE | 2 | 2007 | 2 | 0.140 |
Why?
|
| Mucins | 1 | 2016 | 18 | 0.140 |
Why?
|
| Immunoglobulin E | 2 | 2007 | 36 | 0.140 |
Why?
|
| Receptors, IgG | 2 | 2008 | 7 | 0.140 |
Why?
|
| Spleen | 3 | 2013 | 87 | 0.140 |
Why?
|
| Carbohydrates | 1 | 2016 | 8 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2015 | 483 | 0.140 |
Why?
|
| Cell Survival | 3 | 2006 | 284 | 0.140 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 3 | 2005 | 5 | 0.140 |
Why?
|
| Lectins | 3 | 2005 | 10 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 24 | 0.130 |
Why?
|
| Transcription Factors | 1 | 2017 | 181 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 3 | 2005 | 43 | 0.130 |
Why?
|
| src-Family Kinases | 3 | 2005 | 16 | 0.130 |
Why?
|
| Antigens, CD | 3 | 2005 | 103 | 0.130 |
Why?
|
| Cytokines | 3 | 2008 | 256 | 0.130 |
Why?
|
| Species Specificity | 1 | 2015 | 90 | 0.130 |
Why?
|
| Phenotype | 4 | 2015 | 632 | 0.120 |
Why?
|
| Cross Reactions | 1 | 2014 | 5 | 0.120 |
Why?
|
| Lipopeptides | 1 | 2014 | 6 | 0.120 |
Why?
|
| Phosphatidylcholines | 1 | 2014 | 21 | 0.120 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2014 | 14 | 0.120 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 726 | 0.120 |
Why?
|
| Calcium | 3 | 2006 | 307 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 765 | 0.110 |
Why?
|
| DNA | 1 | 2014 | 226 | 0.110 |
Why?
|
| Diet | 1 | 2015 | 391 | 0.100 |
Why?
|
| Haptens | 1 | 2011 | 1 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 157 | 0.100 |
Why?
|
| Splenectomy | 1 | 2011 | 21 | 0.100 |
Why?
|
| Cysteine | 1 | 2012 | 138 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 835 | 0.090 |
Why?
|
| Immunophenotyping | 4 | 2008 | 50 | 0.090 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2010 | 1 | 0.090 |
Why?
|
| B-Cell Activating Factor | 1 | 2010 | 3 | 0.090 |
Why?
|
| Kidney | 1 | 2014 | 518 | 0.090 |
Why?
|
| Mice, Inbred NZB | 1 | 2010 | 4 | 0.090 |
Why?
|
| Lymphoid Tissue | 2 | 2007 | 10 | 0.090 |
Why?
|
| Terpenes | 1 | 2010 | 7 | 0.090 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 20 | 0.090 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 24 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 1188 | 0.090 |
Why?
|
| Receptors, Fc | 2 | 2006 | 6 | 0.090 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 18 | 0.090 |
Why?
|
| Inflammation | 2 | 2015 | 530 | 0.080 |
Why?
|
| CD40 Ligand | 3 | 2011 | 12 | 0.080 |
Why?
|
| Time Factors | 2 | 2011 | 2149 | 0.080 |
Why?
|
| Models, Biological | 3 | 2007 | 392 | 0.080 |
Why?
|
| Interleukin-10 | 1 | 2008 | 30 | 0.080 |
Why?
|
| Prions | 1 | 2007 | 2 | 0.080 |
Why?
|
| Plasma Cells | 1 | 2008 | 11 | 0.080 |
Why?
|
| Survival Rate | 1 | 2010 | 877 | 0.070 |
Why?
|
| Nippostrongylus | 1 | 2007 | 1 | 0.070 |
Why?
|
| Strongylida Infections | 1 | 2007 | 2 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2007 | 84 | 0.070 |
Why?
|
| Obesity | 1 | 2015 | 1175 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 36 | 0.070 |
Why?
|
| Norepinephrine | 1 | 2006 | 77 | 0.070 |
Why?
|
| Immunity, Cellular | 2 | 2002 | 20 | 0.060 |
Why?
|
| Feedback, Physiological | 1 | 2005 | 10 | 0.060 |
Why?
|
| Scleroderma, Systemic | 1 | 2005 | 7 | 0.060 |
Why?
|
| Immune System | 1 | 2005 | 7 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2003 | 508 | 0.060 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2004 | 2 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 2004 | 2 | 0.060 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2004 | 4 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2004 | 3 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2005 | 71 | 0.060 |
Why?
|
| Vaccines, DNA | 1 | 2004 | 4 | 0.060 |
Why?
|
| Streptavidin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Bacteria | 1 | 2005 | 48 | 0.060 |
Why?
|
| Immunization, Secondary | 1 | 2004 | 11 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 78 | 0.060 |
Why?
|
| Cullin Proteins | 1 | 2004 | 6 | 0.060 |
Why?
|
| HIV-1 | 1 | 2004 | 45 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 35 | 0.060 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2004 | 50 | 0.060 |
Why?
|
| Cell Line | 2 | 2004 | 435 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 55 | 0.060 |
Why?
|
| GTP Phosphohydrolases | 1 | 2003 | 9 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 75 | 0.050 |
Why?
|
| Receptors, Mitogen | 1 | 2002 | 2 | 0.050 |
Why?
|
| Parasitic Diseases | 1 | 2002 | 5 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2002 | 11 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2002 | 11 | 0.050 |
Why?
|
| Mutation | 1 | 2005 | 489 | 0.050 |
Why?
|
| Immunity | 1 | 2002 | 22 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2002 | 59 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2003 | 59 | 0.050 |
Why?
|
| Proteins | 1 | 2003 | 144 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2001 | 71 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2001 | 4 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 14 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2001 | 41 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 105 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2000 | 8 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 101 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2012 | 229 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 173 | 0.040 |
Why?
|
| Disease Progression | 2 | 2012 | 594 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 263 | 0.030 |
Why?
|
| Autoimmune Diseases | 2 | 2008 | 48 | 0.030 |
Why?
|
| Cell Membrane | 2 | 2007 | 96 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2006 | 135 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 23 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2015 | 35 | 0.030 |
Why?
|
| Calcium Signaling | 2 | 2005 | 38 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 566 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 7 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2012 | 8 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 21 | 0.030 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2012 | 10 | 0.030 |
Why?
|
| Cyclohexanones | 1 | 2012 | 18 | 0.030 |
Why?
|
| Actins | 1 | 2012 | 51 | 0.030 |
Why?
|
| Biological Transport | 1 | 2012 | 69 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2015 | 349 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 47 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 185 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 289 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2008 | 1 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 52 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Integrin alpha4beta1 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 48 | 0.020 |
Why?
|
| Prion Diseases | 1 | 2007 | 3 | 0.020 |
Why?
|
| Antigens, Helminth | 1 | 2007 | 1 | 0.020 |
Why?
|
| Alum Compounds | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2007 | 25 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 123 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2007 | 22 | 0.020 |
Why?
|
| Silver | 1 | 2007 | 8 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2006 | 10 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 167 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 36 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2005 | 13 | 0.020 |
Why?
|
| Complement C3 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2005 | 9 | 0.020 |
Why?
|
| Kinetics | 1 | 2005 | 209 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2004 | 32 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 56 | 0.010 |
Why?
|
| Hybridomas | 1 | 2004 | 4 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 91 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 70 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 8 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 169 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 30 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 27 | 0.010 |
Why?
|
| Clone Cells | 1 | 2003 | 36 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2003 | 6 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 85 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 81 | 0.010 |
Why?
|
| Leukocytes | 1 | 2003 | 57 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 64 | 0.010 |
Why?
|
| Blood Cells | 1 | 2003 | 9 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 252 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2003 | 71 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 285 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 247 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 359 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2002 | 9 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2002 | 16 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2003 | 81 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 137 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 3306 | 0.010 |
Why?
|